As the small molecule drug is acting as a plasticizer as well, the greater influence on the polymer resulting from the larger amount added to the blend can be expected. Further increasing the drug content of the blend would lead to lower viscosity at elevated temperatures, but probably also to supersaturated ASDs with the risk of the drug not fully dissolving in the polymer matrix leading to residual drug crystallites in the ASD or accelerated drug crystallization from the oversaturated blends.